Clinical Efficacy of Clotting Factor Concentrates: Survival, Recovery and Hemostatic Capacity
Factor VIII concentrates are necessary for the treatment not only of patients with hemophilia A but also for those with severe von Willebrand’s disease (vWD), especially the type III or the type II variants. Earlier, above all cryoprecipitate, and low and intermediate purity concentrates were used. The intermediate purity concentrates contained 1–3 units of factor VIII clotting activity (FVIII:C) per mg protein, factor VIII itself being only a trace protein. Since 1984, all commercial factor VIII concentrates have been subjected to some form of virus inactivation.In the last years several plasma-derived, superpure factor VIII concentrates have been developed to eliminate the risk of viral transmission, and to reduce other side effects caused by the multiplicity of foreign proteins and alloantigens the concentrates of intermediate purity contain. Clinical trials of recombinant factor VIII have also been started. Correction of the bleeding defect in vWD requires a concentrate containing almost native von Wille rand factor (vWF).
KeywordsFactor VIII Recombinant Factor Viii Severe Hemophilia Factor Viii Concentrate Recombinant Preparation
Unable to display preview. Download preview PDF.
- 1.Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods. Thromb Haemostas 1979;42:1230–9.Google Scholar
- 11.Cinotti S, Boni E, Morfini M. Factor VIII:C potency assay in two rDNA and in plasma derived concentrates. International Symposium on Biotechnology of plasma proteins: Hemostasis, thrombosis and iron proteins. Florence, Italy, April 1990:60(Abstract).Google Scholar
- 13.Barrowcliffe TW, Dawson NJ, Kemball-Cook G. Activated factor VIII in concentrates prepared by monoclonal antibody and recombinant technology.Thromb Haemostas 1989;62:198(Abstract).Google Scholar
- 23.White G, McMillan C, Courter S, Gomperts E and the Recombinate Collaborative Group. Safety and efficacy of antihemophilic factor (recombinant) in hemophilia A patients. Abstract book XIX International Congress of the World Federation of Hemophilia, Washington DC, 1990:25(Abstract 85).Google Scholar